Gadolinium-Enhanced T2 FLAIR is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases

References

1. 1.↵
   1. Tsao MN,
   2. Xu W,
   3. Wong RK, et al

   . Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2018;1:CD003869 doi:10.1002/14651858.CD003869.pub4 pmid:29365347

   CrossRefPubMed
2. 2.↵
   1. Chang EL,
   2. Wefel JS,
   3. Hess KR, et al

   . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037–44 doi:10.1016/S1470-2045(09)70263-3 pmid:19801201

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Aoyama H,
   2. Shirato H,
   3. Tago M, et al

   . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483–91 doi:10.1001/jama.295.21.2483 pmid:16757720

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Brown PD,
   2. Jaeckle K,
   3. Ballman KV, et al

   . Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016;316:401–09 doi:10.1001/jama.2016.9839 pmid:27458945

   CrossRefPubMed
5. 5.↵
   1. Kocher M,
   2. Soffietti R,
   3. Abacioglu U, et al

   . Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134–41 doi:10.1200/JCO.2010.30.1655 pmid:21041710

   Abstract/FREE Full Text
6. 6.↵
   1. Yamamoto M,
   2. Sato Y,
   3. Higuchi Y, et al

   . A cohort study of stereotactic radiosurgery results for patients with 5 to 15 versus 2 to 4 brain metastatic tumors. Adv Radiat Oncol 2020;5:358–68 doi:10.1016/j.adro.2019.11.001 pmid:32529129

   CrossRefPubMed
7. 7.↵
   1. Lütgendorf-Caucig C,
   2. Pelak M,
   3. Hug E, et al

   . Prospective analysis of radiation-induced contrast enhancement and health-related quality of life after proton therapy for central nervous system and skull base tumors. Int J Radiat Oncol Biol Phys 2024;118:1206–16 doi:10.1016/j.ijrobp.2024.01.007 pmid:38244874

   CrossRefPubMed
8. 8.↵
   1. Aizer AA,
   2. Lamba N,
   3. Ahluwalia MS, et al

   . Brain metastases: a Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol 2022;24:1613–46 doi:10.1093/neuonc/noac118 pmid:35762249

   CrossRefPubMed
9. 9.↵
   1. Mayo ZS,
   2. Billena C,
   3. Suh JH, et al

   . The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases. Neuro Oncol 2024;26:S56–65 doi:10.1093/neuonc/noad188 pmid:38437665

   CrossRefPubMed
10. 10.↵
    1. Minniti G,
    2. Clarke E,
    3. Lanzetta G, et al

    . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011;6:48 doi:10.1186/1748-717X-6-48 pmid:21575163

    CrossRefPubMed
11. 11.↵
    1. Faruqi S,
    2. Ruschin M,
    3. Soliman H, et al

    . Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases. Int J Radiat Oncol Biol Phys 2020;106:772–79 doi:10.1016/j.ijrobp.2019.12.002 pmid:31928848

    CrossRefPubMed
12. 12.↵
    1. Soliman H,
    2. Myrehaug S,
    3. Tseng C-L, et al

    . Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases. Neurosurgery 2019;85:E860–69 doi:10.1093/neuros/nyz162 pmid:31173150

    CrossRefPubMed
13. 13.↵
    1. Ahluwalia M,
    2. Barnett GH,
    3. Deng D, et al

    . Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg 2018;130:804–11 doi:10.3171/2017.11.JNS171273 pmid:29726782

    CrossRefPubMed
14. 14.↵
    1. Levin VA,
    2. Bidaut L,
    3. Hou P, et al

    . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487–95 doi:10.1016/j.ijrobp.2009.12.061 pmid:20399573

    CrossRefPubMed
15. 15.↵
    1. Mayo ZS,
    2. Halima A,
    3. Broughman JR, et al

    . Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis. J Neurooncol 2023;161:23–31 doi:10.1007/s11060-022-04225-y pmid:36633800

    CrossRefPubMed
16. 16.↵
    1. Dequesada IM,
    2. Quisling RG,
    3. Yachnis A, et al

    . Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. Neurosurgery 2008;63:898–903; discussion 904 doi:10.1227/01.NEU.0000333263.31870.31 pmid:19005380

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Kano H,
    2. Kondziolka D,
    3. Lobato-Polo J, et al

    . T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 2010;66:486–91; discussion 91–92 doi:10.1227/01.NEU.0000360391.35749.A5 pmid:20173543

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Stockham AL,
    2. Tievsky AL,
    3. Koyfman SA, et al

    . Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol 2012;109:149–58 doi:10.1007/s11060-012-0881-9 pmid:22638727

    CrossRefPubMed
19. 19.↵
    1. Mohamedkhan S,
    2. Hindocha S,
    3. de Boisanger J, et al

    . Contrast clearance analysis (CCA) to assess viable tumour following stereotactic radiosurgery (SRS) to brain metastasis in non-small cell lung cancer (NSCLC). Cancers (Basel) 2024;16:1218 doi:10.3390/cancers16061218 pmid:38539550

    CrossRefPubMed
20. 20.↵
    1. Kim HY,
    2. Cho SJ,
    3. Sunwoo L, et al

    . Classification of true progression after radiotherapy of brain metastasis on MRI using artificial intelligence: a systematic review and meta-analysis. Neurooncol Adv 2021;3:vdab080 doi:10.1093/noajnl/vdab080 pmid:34377988

    CrossRefPubMed
21. 21.↵
    1. Kwee RM,
    2. Kwee TC

    . Dynamic susceptibility MR perfusion in diagnosing recurrent brain metastases after radiotherapy: a systematic review and meta-analysis. J Magn Reson Imaging 2020;51:524–34 doi:10.1002/jmri.26812 pmid:31150144

    CrossRefPubMed
22. 22.↵
    1. Kaufmann TJ,
    2. Smits M,
    3. Boxerman J, et al

    . Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol 2020;22:757–72 doi:10.1093/neuonc/noaa030 pmid:32048719

    CrossRefPubMed
23. 23.↵
    1. Mathews VP,
    2. Caldemeyer KS,
    3. Lowe MJ, et al

    . Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology 1999;211:257–63 doi:10.1148/radiology.211.1.r99mr25257 pmid:10189481

    CrossRefPubMed
24. 24.↵
    1. Griffiths PD,
    2. Coley SC,
    3. Romanowski CA, et al

    . Contrast-enhanced fluid-attenuated inversion recovery imaging for leptomeningeal disease in children. AJNR Am J Neuroradiol 2003;24:719–23 pmid:12695212

    Abstract/FREE Full Text
25. 25.↵
    1. Parmar H,
    2. Sitoh YY,
    3. Anand P, et al

    . Contrast-enhanced flair imaging in the evaluation of infectious leptomeningeal diseases. Eur J Radiol 2006;58:89–95 doi:10.1016/j.ejrad.2005.11.012 pmid:16386866

    CrossRefPubMed
26. 26.↵
    1. Fukuoka H,
    2. Hirai T,
    3. Okuda T, et al

    . Comparison of the added value of contrast-enhanced 3D fluid-attenuated inversion recovery and magnetization-prepared rapid acquisition of gradient echo sequences in relation to conventional postcontrast T1-weighted images for the evaluation of leptomeningeal diseases at 3T. AJNR Am J Neuroradiol 2010;31:868–73 doi:10.3174/ajnr.A1937 pmid:20037130

    Abstract/FREE Full Text
27. 27.↵
    1. Bossuyt PM,
    2. Reitsma JB,
    3. Bruns DE

    ; STARD Group, et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Radiology 2015;277:826–32 doi:10.1148/radiol.2015151516 pmid:26509226

    CrossRefPubMed
28. 28.↵
    1. Heyn C,
    2. Moody AR,
    3. Tseng C-L, et al

    . Segmentation of brain metastases using background layer statistics (BLAST). AJNR Am J Neuroradiol 2023;44:1135–43 doi:10.3174/ajnr.A7998 pmid:37735088

    Abstract/FREE Full Text
29. 29.↵
    1. Mehrabian H,
    2. Chan RW,
    3. Sahgal A, et al

    . Chemical exchange saturation transfer MRI for differentiating radiation necrosis from tumor progression in brain metastasis-application in a clinical setting. J Magn Reson Imaging 2023;57:1713–25 doi:10.1002/jmri.28440 pmid:36219521

    CrossRefPubMed
30. 30.↵
    1. Lin NU,
    2. Lee EQ,
    3. Aoyama H, et al

    ; Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015;16:e270–78 doi:10.1016/S1470-2045(15)70057-4 pmid:26065612

    CrossRefPubMed
31. 31.↵
    1. Peng L,
    2. Parekh V,
    3. Huang P, et al

    . Distinguishing true progression from radionecrosis after stereotactic radiation therapy for brain metastases with machine learning and radiomics. Int J Radiat Oncol Biol Phys 2018;102:1236–43 doi:10.1016/j.ijrobp.2018.05.041 pmid:30353872

    CrossRefPubMed
32. 32.↵
    1. Shiroishi MS,
    2. Castellazzi G,
    3. Boxerman JL, et al

    . Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging 2015;41:296–313 doi:10.1002/jmri.24648 pmid:24817252

    CrossRefPubMed
33. 33.↵
    1. Quarles CC,
    2. Gochberg DF,
    3. Gore JC, et al

    . A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol 2009;54:5749–66 doi:10.1088/0031-9155/54/19/006 pmid:19729712

    CrossRefPubMed